Clinical Trials · NCT00186121

Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women

CompletedPhase 2Gonadorelin (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Stanford University
Enrollment
35
Start date
Oct 2000
Locations
1 site, United States
Primary endpoint
Objective Response Rate (ORR)
View Gonadorelin compound reference